ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Swedish Orphan Biovitrum and Takeda side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Swedish Orphan BiovitrumTakeda
studies on the registry1371,754
open to participants now686
phase 3 studies under way544
reach primary completion within a year447
programswith a study of their own in two years725

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSwedish Orphan BiovitrumTakeda
Phase 100%

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
Phase 2

Swedish Orphan Biovitrum: 1 of its 7 programs at phase 2

  1. XOI Low Dosephase 2
14%

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%
Phase 3

Swedish Orphan Biovitrum: 2 of its 7 programs at phase 3

  1. pacritinibphase 3
  2. AR882phase 3
29%

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%
Approved, new studies

Swedish Orphan Biovitrum: 4 of its 7 programs at approved, new studies

  1. efanesoctocog alfaapproved, new study
  2. pegcetacoplanapproved, new study
  3. avatrombopagapproved, new study
  4. Interleukin 1 Receptor Antagonist Proteinapproved, new study
57%

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Swedish Orphan Biovitrum4 readouts · 1 phase 3

Swedish Orphan Biovitrum, Nov ’26: 2 programs whose next study reaches primary completion

  1. AR882phase 3 · Nov 0 · NCT07116746
  2. XOI Low Dosephase 2 · Nov 0 · NCT07116746

Swedish Orphan Biovitrum, Dec ’26: 1 program whose next study reaches primary completion

  1. pacritinibphase 3 · Dec 30 · NCT06782373
··

Swedish Orphan Biovitrum, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Mar 0 · NCT06716814
·······
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Swedish Orphan Biovitrum

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionSwedish Orphan BiovitrumTakeda
Hodgkin Diseaseboth · compare here

Swedish Orphan Biovitrum in Hodgkin Disease: 1 program

  1. pacritinibphase 3

Their studies: Swedish Orphan Biovitrum’s studies of Hodgkin Disease in search

Takeda in Hodgkin Disease: 2 programs

  1. Brentuximab Vedotinapproved, new study
  2. Vinblastineapproved, new study

Their studies: Takeda’s studies of Hodgkin Disease in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

Swedish Orphan Biovitrum in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. avatrombopagapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Takeda in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. mezagitamabphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Purpura, Thrombocytopenic, Idiopathic in search

von Willebrand Diseasesboth · compare here

Swedish Orphan Biovitrum in von Willebrand Diseases: 1 program

  1. efanesoctocog alfaapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of von Willebrand Diseases in search

Takeda in von Willebrand Diseases: 2 programs

  1. vonicog alfaphase 3
  2. antihemophilic factor, human recombinantapproved, new study

Their studies: Takeda’s studies of von Willebrand Diseases in search

Hemophilia Aboth · compare here

Swedish Orphan Biovitrum in Hemophilia A: 1 program

  1. efanesoctocog alfaapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Hemophilia A in search

Takeda in Hemophilia A: 1 program

  1. antihemophilic factor, human recombinantapproved, new study

Their studies: Takeda’s studies of Hemophilia A in search

Primary Myelofibrosisboth · compare here

Swedish Orphan Biovitrum in Primary Myelofibrosis: 1 program

  1. pacritinibphase 3

Their studies: Swedish Orphan Biovitrum’s studies of Primary Myelofibrosis in search

Takeda in Primary Myelofibrosis: 1 program

  1. elriterceptphase 3

Their studies: Takeda’s studies of Primary Myelofibrosis in search

Renal Insufficiencyboth · compare here

Swedish Orphan Biovitrum in Renal Insufficiency: 1 program

  1. AR882phase 3

Their studies: Swedish Orphan Biovitrum’s studies of Renal Insufficiency in search

Takeda in Renal Insufficiency: 1 program

  1. teduglutidephase 3

Their studies: Takeda’s studies of Renal Insufficiency in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetSwedish Orphan BiovitrumTakeda
F8efanesoctocog alfaruleantihemophilic factor, human recombinantrule
A target, or a pathogen for a vaccine, known for: Swedish Orphan Biovitrum 5 of 7 · Takeda 12 of 25 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.